The Eli Lilly and Co. (LLY) Stake Maintained by Hanson & Doremus Investment Management

The Eli Lilly and Co. (LLY) Stake Maintained by Hanson & Doremus Investment Management

Hanson & Doremus Investment Management continued to hold its stake in shares of Eli Lilly and Co. (NYSE:LLY) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,298 shares of the company’s stock at the end of the second quarter. Hanson & Doremus Investment Management’s holdings in Eli Lilly and were worth $338,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Ausdal Financial Partners Inc. raised its stake in Eli Lilly and by 4.4% in the second quarter. Ausdal Financial Partners Inc. now owns 2,983 shares of the company’s stock worth $235,000 after buying an additional 126 shares in the last quarter. Tocqueville Asset Management L.P. raised its stake in Eli Lilly and by 238.4% in the second quarter. Tocqueville Asset Management L.P. now owns 44,768 shares of the company’s stock worth $3,525,000 after buying an additional 31,537 shares in the last quarter. FTB Advisors Inc. raised its stake in Eli Lilly and by 8.4% in the second quarter. FTB Advisors Inc. now owns 21,297 shares of the company’s stock worth $1,676,000 after buying an additional 1,642 shares in the last quarter. Signaturefd LLC raised its stake in Eli Lilly and by 16.1% in the second quarter. Signaturefd LLC now owns 1,796 shares of the company’s stock worth $141,000 after buying an additional 249 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its stake in Eli Lilly and by 0.7% in the second quarter. Kornitzer Capital Management Inc. KS now owns 317,650 shares of the company’s stock worth $25,015,000 after buying an additional 2,145 shares in the last quarter. 74.99% of the stock is currently owned by institutional investors.

Shares of Eli Lilly and Co. (NYSE:LLY) traded down 0.87% on Monday, reaching $78.58. 2,115,169 shares of the company’s stock were exchanged. The company has a market capitalization of $83.11 billion, a P/E ratio of 33.87 and a beta of 0.17. The stock’s 50-day moving average price is $79.73 and its 200-day moving average price is $77.79. Eli Lilly and Co. has a 1-year low of $67.88 and a 1-year high of $88.16.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The business earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. During the same period in the previous year, the business posted $0.90 EPS. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Analysts anticipate that Eli Lilly and Co. will post $3.59 EPS for the current fiscal year.

LLY has been the topic of a number of recent research reports. Jefferies Group upped their price objective on Eli Lilly and from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, July 14th. Goldman Sachs Group Inc. upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $89.00 to $95.00 in a research note on Tuesday, September 27th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Argus boosted their target price on shares of Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Eli Lilly and from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $92.00 to $95.00 in a research note on Thursday, September 8th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Buy” and an average target price of $97.06.

In other news, insider Donald A. Zakrowski sold 1,213 shares of Eli Lilly and stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the transaction, the insider now directly owns 1,300 shares of the company’s stock, valued at approximately $108,108. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Maria A. Crowe sold 2,248 shares of Eli Lilly and stock in a transaction dated Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now directly owns 94,319 shares of the company’s stock, valued at $7,674,737.03. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Related posts

Leave a Comment